Out Of The Pipeline
Out Of The Pipeline
Dexmedetomidine sublingual film for agitation
Approved by the FDA on April 5, 2022, dexmedetomidine sublingual film (Igalmi, manufactured and distributed by BioXcel Therapeutics, Inc., New...
Out Of The Pipeline
Lumateperone for major depressive episodes in bipolar I or bipolar II disorder
Among patients with bipolar I or II disorder (BD I or II), major depressive episodes represent the predominant mood state when not euthymic, and...
Out Of The Pipeline
Olanzapine-samidorphan combination for schizophrenia or bipolar I disorder
Approved by the FDA on May 28, 2021, olanzapine-samidorphan combination (OSC) (Lybalvi, manufactured and distributed by Alkermes, Inc. Waltham, MA...
Out Of The Pipeline
Asenapine transdermal system for schizophrenia
Approved by the FDA on October 11, 2019, asenapine transdermal system (Secuado, manufactured by Hisamitsu Pharmaceutical Co., Inc. and distributed...
Out Of The Pipeline
Lemborexant for insomnia
Lemborexant, FDA-approved for the treatment of insomnia, has demonstrated efficacy in improving both sleep onset and sleep maintenance.
Out Of The Pipeline
Lumateperone for schizophrenia
Lumateperone is a novel oral antipsychotic approved for the treatment of adult patients with schizophrenia.
Out Of The Pipeline
Brexanolone injection for postpartum depression
First-in-class neuroactive steroid was recently FDA-approved for treating adults with postpartum depression.
Out Of The Pipeline
Intranasal esketamine
Treatment-resistant depression (TRD) is a common clinical struggle that practicing clinicians address on a daily basis. Major depressive disorder...
Out Of The Pipeline
Risperidone extended-release injectable suspension
RBP-7000 (Perseris) is the second long-acting injectable form of risperidone
approved in the United States.
Out Of The Pipeline
Aripiprazole lauroxil nanocrystal suspension
New long-acting injectable formulation simplifies the initiation regimen.
Out Of The Pipeline
Deutetrabenazine for tardive dyskinesia
Compared with first-generation antipsychotics, second-generation antipsychotics (SGAs) have a lower risk for extrapyramidal symptoms. Yet tardive...